Arena Pharmaceuticals Incorporated (NASDAQ:ARNA) Can't Be Less Risky. Short Interest Decreased

Claudine Rigal
Juin 19, 2017

They now have a United States dollars 4 price target on the stock.

Several other equities research analysts also recently commented on ARNA. Leerink Swann assumed coverage on Arena Pharmaceuticals in a research note on Friday, May 19th. They now have a Dollars 6 price target on the stock. FBR & Co restated an "outperform" rating and issued a $60.00 target price on shares of Arena Pharmaceuticals in a research note on Thursday, March 16th. (ARNA) has weekly volatility of 5.19%% while its monthly volatility value is at 4.93%%.

After a recent check, Arena Pharmaceuticals, Inc. (NYSE:NTIP), its shares were trading at $3.9 a retreat of $-0.25, on the trading floor. If you are viewing this story on another publication, it was stolen and republished in violation of USA & global trademark and copyright law.

Arena Pharmaceutical (NASDAQ:ARNA)'s revenue estimates for the current quarter are $5.4 Million according to 7 number of analysts, for the current quarter the company has high revenue estimates of $8.5 Million in contradiction of low revenue estimates of $3.1 Million. Arena Pharmaceuticals, Inc. has far performed well this year, with the share price down -11.27% since January.

The stock of Arena Pharmaceuticals Incorporated (NASDAQ:ARNA) registered a decrease of 0.75% in short interest. Breaking that down further, it has performed -3.68% for the week, 13.91% for the month, -15.48% over the last quarter, -9.03% for the past half-year and -30.69% for this previous year. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -5.76% where SMA50 and SMA200 are -5.43% and -15.15% respectively. (NASDAQ:ARNA) for 386,100 shares. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. Return on Equity (ROE) stands at -110.4% and Return on Investment (ROI) of -16.3 percent.

Over the last 5 years, Arena Pharmaceuticals, Inc. has averaged a 35.00% YoY EPS growth rate and a 57.70% revenue growth rate.

Banco Bradesco Sa (NYSE:BBD) has average revenue estimates of $8.38 Billion, compared to low analyst estimates of $8.26 Billion and high estimates of $8.49 Billion for the current quarter. The company's revenue for the quarter was down 33.0% compared to the same quarter a year ago.

A number of large investors have recently added to or reduced their stakes in ARNA. Finally, Wellington Management Group LLP raised its position in shares of Arena Pharmaceuticals by 2.4% in the first quarter. Tudor Investment Corp Et Al now owns 72,259 shares of the biopharmaceutical company's stock worth $103,000 after buying an additional 48,181 shares in the last quarter. Schwab Charles Investment Management Inc. now owns 1,078,955 shares of the biopharmaceutical company's stock valued at $1,576,000 after buying an additional 215,844 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in shares of Arena Pharmaceuticals by 11.4% in the first quarter. NY now owns 172,165 shares of the biopharmaceutical company's stock valued at $251,000 after buying an additional 17,565 shares during the period. Bank of America Corp DE increased its stake in shares of Arena Pharmaceuticals by 102.0% in the first quarter. Tudor Investment Corp ET AL now owns 141,225 shares of the biopharmaceutical company's stock valued at $206,000 after buying an additional 68,966 shares during the period.

D E Shaw And Inc accumulated 97,419 shares. Market Capitalization if basically the market value of the company's shares outstanding. Cantor Fitzgerald initiated coverage on Arena Pharmaceuticals in a research note on Thursday. The stock was purchased at an average price of $1.41 per share, with a total value of $70,500.00.

Since May 12, 2017, it had 1 buy, and 0 insider sales for $29,750 activity. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL